Purification of monoclonal antibodies by epitope and mimotope affinity chromatography

Murray, Andrea; Sekowski, M.; Spencer, Daniel I. R.; Denton, G.; Price, Michael R.

doi:10.1016/s0021-9673(97)00674-2

Cited by 30 publications

(14 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Epitope chromatography was used for the purification of anti-epithelial mucin monoclonal antibodies with applications in the diagnosis and therapy of human breast and ovarian cancer. It was found that these Mab's react with a peptide (PDTRPAP), which after coupling to Sepharose proved to be an efficient adsorbent for Mabrecovery, from either hybridoma tissue cultures (154,155) or ascites fluids (156). A peptide mimotope (mimicking a non-proteinaceous antigen) has been further generated by combined biological (phage display) and chemical combinatorial techniques for paratopespecific purification of Mab's (157).…”

Section: Peptidic Ligandsmentioning

confidence: 99%

Antibodies and Genetically Engineered Related Molecules: Production and Purification

Roque

Lowe

Taipa³

2004

Biotechnol. Prog.

328

203

View full text Add to dashboard Cite

Antibodies and antibody derivatives constitute 20 % of biopharmaceutical products currently in development, and despite early failures of murine products, chimeric and humanized monoclonal antibodies are now viable therapeutics. A number of genetically engineered antibody constructions have emerged, including molecular hybrids or chimeras that can deliver a powerful toxin to a target such as a tumor cell. However, the general use in clinical practice of antibody therapeutics is dependent not only on the availability of products with required efficacy but also on the costs of therapy. As a rule, a significant percentage (50-80%) of the total manufacturing cost of a therapeutic antibody is incurred during downstream processing. The critical challenges posed by the production of novel antibody therapeutics include improving process economics and efficiency, to reduce costs, and fulfilling increasingly demanding quality criteria for Food and Drug Administration (FDA) approval. It is anticipated that novel affinity-based separations will emerge from the development of synthetic ligands tailored to specific biotechnological needs. These synthetic affinity ligands include peptides obtained by synthesis and screening of peptide combinatorial libraries and artificial non-peptidic ligands generated by a de novo process design and synthesis. The exceptional stability, improved selectivity, and low cost of these ligands can lead to more efficient, less expensive, and safer procedures for antibody purification at manufacturing scales. This review aims to highlight the current trends in the design and construction of genetically engineered antibodies and related molecules, the recombinant systems used for their production, and the development of novel affinity-based strategies for antibody recovery and purification.

show abstract

Section: Peptidic Ligandsmentioning

confidence: 99%

Antibodies and Genetically Engineered Related Molecules: Production and Purification

Roque

Lowe

Taipa³

2004

Biotechnol. Prog.

328

203

View full text Add to dashboard Cite

show abstract

“…This resulted in enhanced chromatographic performance providing antibody preparations of molecular homogeneity and high immunoreactivity. The relatively low concentration of NaSCN required to desorb antibody from the matrix would suggest that the affinity of the interaction is low (2). Nevertheless, good separations were achieved with no nonspecific binding of contaminating proteins or irrelevant antibody being observed.…”

Section: Discussionmentioning

confidence: 99%

Generation and Refinement of Peptide Mimetic Ligands for Paratope-Specific Purification of Monoclonal Antibodies

Murray

Smith

Brady

et al. 2001

Analytical Biochemistry

Self Cite

View full text Add to dashboard Cite

“…Synthetic peptides corresponding to the immunodominant region have been used as ligands for the purification of a range of anti-MUCi monoclonal antibodies and antibody fragments using epitope affinity chromatography (21)(22)(23). In these experiments, highly pure and immunoreactive anti-MUCi antibodies were isolated from crude feedstocks by adsorption to and subsequent elution from the immunoaffinity matrix.…”

Section: Introductionmentioning

confidence: 99%

Design of ligands for the purification of anti‐MUC₁ antibodies by peptide epitope affinity chromatography

Murray

Spencer

Missailidis

et al. 1998

The Journal of Peptide Research

View full text Add to dashboard Cite

To cite this article: Murray. A , Spencer, D I R , Missailidn, S., Denton, G.. d Price, M.R. (1998) Design of ligands for the purification of anti-MUCi antibodies by peptide epitope affinity chromatography. / Peptide Res 52, 375-383. Abstract: The fine specificity of epitope recognition of the anti-MUCl mucin monoclonal antibody, C595 has been studied using solid-phase replacement net (RNET) analysis. Two peptides (RAAP and RPPP) showed increased reactivity with C595 antibody 37s Murray et d . Peptide ligands for antibody purification Abbreviations: MUC1, polymorphic epithelial mucin, product of the MUCl gene; RNET, replacement net; FQ, fluorescence quenching; CD, circular dichroism; PBS, phosphate buffered saline; BSA, bovine serum albumin; HRP, horseradish peroxidase; ABTS. 2.2-azino bis (3-ethylbenzothiazoline-6-sulphonic acid); SDS. sodium dodecyl sulfate; FPLC, Fast Protein Liquid Chromatography;ELISA, enzyme-linked immunosorbant assay; PAGE, polyacrylamide gel electrophoresis; PII, type II poly-proline helix.

show abstract

Purification of monoclonal antibodies by epitope and mimotope affinity chromatography

Cited by 30 publications

References 10 publications

Antibodies and Genetically Engineered Related Molecules: Production and Purification

Antibodies and Genetically Engineered Related Molecules: Production and Purification

Generation and Refinement of Peptide Mimetic Ligands for Paratope-Specific Purification of Monoclonal Antibodies

Design of ligands for the purification of anti‐MUC₁ antibodies by peptide epitope affinity chromatography

Contact Info

Product

Resources

About

Purification of monoclonal antibodies by epitope and mimotope affinity chromatography

Cited by 30 publications

References 10 publications

Antibodies and Genetically Engineered Related Molecules: Production and Purification

Antibodies and Genetically Engineered Related Molecules: Production and Purification

Generation and Refinement of Peptide Mimetic Ligands for Paratope-Specific Purification of Monoclonal Antibodies

Design of ligands for the purification of anti‐MUC1 antibodies by peptide epitope affinity chromatography

Contact Info

Product

Resources

About

Design of ligands for the purification of anti‐MUC₁ antibodies by peptide epitope affinity chromatography